Selected article for: "acute respiratory syndrome and high risk"
Author: Ahn, Jin Young; Sohn, Yujin; Lee, Su Hwan; Cho, Yunsuk; Hyun, Jong Hoon; Baek, Yae Jee; Jeong, Su Jin; Kim, Jung Ho; Ku, Nam Su; Yeom, Joon-Sup; Roh, Juhye; Ahn, Mi Young; Chin, Bum Sik; Kim, Young Sam; Lee, Hyukmin; Yong, Dongeun; Kim, Hyun Ok; Kim, Sinyoung; Choi, Jun Yong
Title: Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea
  • Document date: 2020_4_6
    • ID: 1uwir5b8_1
    Snippet: An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which began in Wuhan, China, has emerged as a primary concern all over the world. The World Health Organization announced the risk assessment of coronavirus disease 2019 as very high at the global level, and fatal cases are rapidly increasing. By March 24, 2020, more than 9,000 people were infected, and 126 people died, in South Korea. Without specific treatmen.....
    Document: An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, which began in Wuhan, China, has emerged as a primary concern all over the world. The World Health Organization announced the risk assessment of coronavirus disease 2019 as very high at the global level, and fatal cases are rapidly increasing. By March 24, 2020, more than 9,000 people were infected, and 126 people died, in South Korea. Without specific treatments for the virus, treatment options are being studied in addition to supportive care. Evidence shows that the use of convalescent plasma to treat emerging viral infections, including SARS, Middle East respiratory syndrome (MERS), Ebola virus disease or avian flu, can improve survival rates in patients whose condition worsens even with conventional treatment. 1,2 However, the safety and efficacy of convalescent plasma treatment in COVID- 19 have not been known. Here, we report two cases of severe COVID-19 patients presenting acute respiratory distress syndrome (ARDS), who showed a favorable clinical course after the convalescent plasma infusion. This is the first report of the use of convalescent plasma to treat cases of SARS-CoV-2 infection in Korea.

    Search related documents:
    Co phrase search for related documents
    • acute ARDS respiratory distress syndrome and avian flu: 1
    • acute ARDS respiratory distress syndrome and clinical course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and convalescent plasma treatment: 1, 2, 3, 4, 5, 6, 7
    • acute ARDS respiratory distress syndrome and conventional treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ARDS respiratory distress syndrome and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and Ebola virus: 1, 2
    • acute ARDS respiratory distress syndrome and Ebola virus disease: 1, 2
    • acute ARDS respiratory distress syndrome and efficacy safety: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ARDS respiratory distress syndrome and fatal case: 1, 2, 3, 4, 5, 6
    • ARDS respiratory distress syndrome and avian flu: 1
    • ARDS respiratory distress syndrome and clinical course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ARDS respiratory distress syndrome and convalescent plasma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ARDS respiratory distress syndrome and convalescent plasma treatment: 1, 2, 3, 4, 5, 6, 7
    • ARDS respiratory distress syndrome and conventional treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ARDS respiratory distress syndrome and distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ARDS respiratory distress syndrome and Ebola virus: 1, 2
    • ARDS respiratory distress syndrome and Ebola virus disease: 1, 2
    • ARDS respiratory distress syndrome and efficacy safety: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25